Characteristics of RSV-specific maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Jans, Jop ^a   Wicht, Oliver ^a,b   Widjaja, Ivy ^c   Ahout, Inge M L ^a   De Groot, Ronald ^a   Guichelaar, Teun ^b   Luytjes, Willem ^b   De Jonge, Marien I ^a   De Haan, Cornelis A M ^c   Ferwerda, Gerben ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VITRO STUDY; INTENSIVE CARE UNIT; LIMIT OF QUANTITATION; MALE; MATERNAL PLASMA; NONHUMAN; OXYGEN SATURATION; OXYGEN THERAPY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TACHYPNEA; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; ACUTE DISEASE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BLOOD; IMMUNOLOGY; INFANT; SERODIAGNOSIS; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; EPITOPES; FEMALE; GLYCOPROTEINS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEVERITY OF ILLNESS INDEX;

EID: 85011290090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170877     Document Type: Article

References (33)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. Lancet. 2010; 375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1 PMID: 20399493
2. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics. 2010; 125 (2):342-9. doi: 10.1542/peds.2009-2092 PMID: 20100768
3. Chu HY, Steinhoff MC, Magaret A, Zaman K, Roy E, Langdon G, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. The Journal of infectious diseases. 2014; 210(10):1582-9. Epub 2014/06/07. doi: 10.1093/infdis/jiu316 PMID: 24903663
4. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981; 98(5):708-15. PMID: 7229749
5. Vissers M, Hartman Y, Groh L, de Jong DJ, de Jonge MI, Ferwerda G. Recognition of Streptococcus pneumoniae and muramyl dipeptide by NOD2 results in potent induction of MMP-9, which can be controlled by lipopolysaccharide stimulation. Infect Immun. 2014; 82(12):4952-8. doi: 10.1128/IAI.02150-14 PMID: 25183734
6. van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol J. 2012; 9:253. doi: 10.1186/1743-422X-9-253 PMID: 23114196
7. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J. 2010; 7:114. doi: 10.1186/1743-422X-7-114 PMID: 20525213
8. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infection and immunity. 2002; 70(2):584-90. doi: 10.1128/IAI.70.2.584-590.2002 PMID: 11796586
9. Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, et al. Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. PloS one. 2015; 10(6):e0130829. doi: 10.1371/journal.pone.0130829 PMID: 26107504
10. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013; 8(8):e71072. doi: 10.1371/journal.pone.0071072 PMID: 23951084
11. Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJ, van Kuppeveld FJ, et al. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. J Virol. 2016; 90(13):5965-77. doi: 10.1128/JVI. 00235-16 PMID: 27099320
12. Wright PF, Gruber WC, Peters M, Reed G, Zhu Y, Robinson F, et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. The Journal of infectious diseases. 2002; 185(8):1011-8. doi: 10.1086/339822 PMID: 11930309
13. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009; 15(1):34-41. doi: 10.1038/nm.1894 PMID: 19079256
14. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986; 24(2):197-202. PMID: 3755730
15. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol. 1996; 70(11):7783-91. PMID: 8892899
16. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015; 7 (309):309ra162.
17. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1992; 73 (Pt 9):2225-34.
18. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. doi: 10.1128/JVI.00555-11 PMID: 21613394
19. Nyiro JU, Sande C, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, et al. Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya. Vaccine. 2015; 33(15):1797-801. Epub 2015/03/01. doi: 10.1016/j.vaccine.2015.02.039 PMID: 25725445
20. Atwell JE, Thumar B, Robinson LJ, Tobby R, Yambo P, Ome-Kaius M, et al. Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. The Journal of infectious diseases. 2016; 213(3):423-31. Epub 2015/08/05. doi: 10.1093/infdis/jiv401 PMID: 26238686
21. van der Zalm MM, Uiterwaal CS, Wilbrink B, de Jong BM, Verheij TJ, Kimpen JL, et al. Respiratory pathogens in respiratory tract illnesses during the first year of life: a birth cohort study. The Pediatric infectious disease journal. 2009; 28(6):472-6. Epub 2009/06/09. PMID: 19504730
22. Freitas GR, Silva DA, Yokosawa J, Paula NT, Costa LF, Carneiro BM, et al. Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children. J Med Virol. 2011; 83(10):1826-33. doi: 10.1002/jmv.22134 PMID: 21837801
23. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infectious diseases and therapy. 2016; 5(3):271-98. Epub 2016/08/03. doi: 10.1007/s40121-016-0123-0 PMID: 27480325
24. Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol. 2009; 123(2):398-403. doi: 10.1016/j.jaci.2008.10.043 PMID: 19101023
25. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, et al. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med. 2015; 191(9):1040-9. doi: 10.1164/rccm.201412-2256OC PMID: 25730467
26. Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. The Pediatric infectious disease journal. 2008; 27(3):207-12. doi: 10.1097/INF.0b013e31815ac585 PMID: 18277934
27. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405-21. PMID: 4305197
28. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010; 16(1):123-8. doi: 10.1038/nm.2071 PMID: 20023635
29. Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. The Journal of infectious diseases. 2008; 198(7):1007-15. doi: 10.1086/591460 PMID: 18702606
30. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature communications. 2015; 6:8143.
31. McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol. 2015; 89(13):6835-47. doi: 10.1128/JVI.00384-15 PMID: 25903340
32. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002; 196(6):859-65. doi: 10.1084/jem. 20020781 PMID: 12235218
33. Gomez RS, Ramirez BA, Cespedes PF, Cautivo KM, Riquelme SA, Prado CE, et al. Contribution of Fcgamma receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells. Immunology. 2016; 147(1):55-72. doi: 10.1111/imm.12541 PMID: 26451966